Company intelligence / Profile preview
Jinpai Chizhengtang Pharmaceutical
Hubei Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Jinpai Chizhengtang Pharmaceutical is a private Chinese pharmaceutical company focused on the development of herbal medicines for infectious and respiratory diseases. Its lead product, Qingfei Dayuan Granules, is in Phase 2 clinical trials for influenza. The company appears to have a narrow pipeline with one main clinical-stage asset and no disclosed advanced technology platforms or partnerships[1].
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Herbal medicineSmall molecule (inferred, as herbal medicines are composed of small molecules)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Jinpai Chizhengtang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jinpai Chizhengtang Pharmaceutical.